MACS GMP PepTivator

GMP PepTivator
EBV BZLF1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap. It has been developed for efficient
in vitro
stimulation and subsequent isolation of EBV BZLF1–specific CD4
and CD8
T cells.


MACS GMP Products are for research use and
ex vivo
cell culture processing only, and are not intended for human
in vivo
applications. For regulatory status in the USA, please contact your local representative.

Background information

Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and carcinogenic potential. More than 90% of human adults are infected with EBV. In healthy individuals, EBV typically establishes a persistent latent infection, in which the virus can be detected in resting, non-proliferating peripheral B lymphocytes.
BZLF1 is a transcriptional activator and regulates a promoter of an EBV gene. It plays a key role in the switch from latent to productive EBV infection.


T cells are essential for the control of the outgrowth of EBV-infected B cells. BZLF1-specific CD4
and CD8
T cells have been found in EBV-infected individuals.
Adoptive transfer of BZLF1-specific T cells may be an effective tool for the treatment of EBV-associated malignancies.
In vitro
stimulation of BZLF1-specific CD4
and CD8
T cells with MACS GMP PepTivator EBV BZLF1 causes the production of the effector cytokine IFN-γ. The secretion of IFN-γ then permits the enrichment of BZLF1-specific effector/memory T cells using the CliniMACS
Cytokine Capture System (IFN-gamma).

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
  • Selected references

    1. Bogedain, C. et al. (1995) Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J. Virol. 69: 4872-4879
    2. Saulquin et al. (2000) A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur. J. Immunol. 30: 2531-2539
    3. Precopio, M. L. et al. (2003) Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol. 170: 2590-2598
    4. Tynan, F. E. et al. (2005) The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J. Exp. Med. 202: 1249-1260
  • Certificates

    Please follow this
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 1
stimulation of
SEK 22 955,00 

Related products

6 products available | view all